Protein Kinases in Drug Discovery
- 1st Edition, Volume 124 - February 22, 2021
- Imprint: Academic Press
- Editor: Rossen Donev
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 3 1 3 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 3 1 4 - 9
Protein Kinases in Drug Discovery, Volume 124 discusses the latest information on protein kinases and how they modify other proteins by chemically adding phosphate groups to them.… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteProtein Kinases in Drug Discovery, Volume 124 discusses the latest information on protein kinases and how they modify other proteins by chemically adding phosphate groups to them. New chapters in this release include Transport Proteins and AMPs: Implications in Human Disease, Protein kinase CK2 inhibition as a pharmacological strategy, Emerging role of Protein kinase in diabetes mellitus: From Mechanism to therapy, Dual Roles of ATP-binding site in Protein Kinases: Orthosteric inhibition and Allosteric Regulation, Pseudokinases in drug discovery and development: progress, challenges and future prospects, Comparison of knowledge-based vs. combinatorial peptide library approaches for the identification of protein kinase substrates, and more.
- Contains timely chapters written by well-renown authorities in their field
- Includes a number of high-quality illustrations, figures and tables, and targets a very wide audience of specialists, researchers and students
- Integrates experimental and computational methods for studying the role of protein kinases in different diseases, along with sections on the design of suitable protein kinase inhibitors for use in the treatment of patients
Protein chemists, molecular cell biologists, immunologists, structural biologists, computational biochemists, medical doctors, pharmacologists and other researchers working in the field of transport proteins and drug design. Medical, biology and pharmacology students specializing in this field
1. Transporter proteins and its implication in human diseases
Ritika Kabra and Shailza Singh
2. Protein kinase CK2 inhibition as a pharmacological strategy
Christian Borgo and Maria Ruzzene
3. Emerging role of protein kinases in diabetes mellitus: From mechanism to therapy
Preeti Gupta, Aaliya Taiyab, and Md Imtaiyaz Hassan
4. Dual roles of ATP-binding site in protein kinases: Orthosteric inhibition and allosteric regulation
Mingyu Li, Ashfaq Ur Rehman, Yaqin Liu, Kai Chen, and Shaoyong Lu
5. Pseudokinases: Prospects for expanding the therapeutic targets armamentarium
Nayana Devang, Adyashree Pani, and G.K. Rajanikant
6. Chemogenomics and bioinformatics approaches for prioritizing kinases as drug targets for neglected tropical diseases
Joyce Villa Verde Bastos Borba, Arthur Carvalho Silva, Marilia Nunes Nascimento Lima, Sabrina Silva Mendonca, Nicholas Furnham, Fabio Trindade Maranhão Costa, and Carolina Horta Andrade
7. Targeting malaria protein kinases
G.C. Cassiano, T.A. Tavella, M.N. Nascimento, D.A. Rodrigues, P.V.L. Cravo, Carolina Horta Andrade, and Fabio Trindade Maranhão Costa
8. Yeast-based high-throughput screens for discovery of kinase inhibitors for neglected diseases
T.A. Tavella, G.C. Cassiano, Fabio Trindade Maranhão Costa, P. Sunnerhagen, and E. Bilsland
9. Structural studies of full-length receptor tyrosine kinases and their implications for drug design
Adam Bajinting and Ho Leung Ng
- Edition: 1
- Volume: 124
- Published: February 22, 2021
- No. of pages (Hardback): 350
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780323853132
- eBook ISBN: 9780323853149
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UKRead Protein Kinases in Drug Discovery on ScienceDirect